Keywords: Cancer drug development, Roche, Novartis, Citeline, Merck KGaA, Boehringer Ingelheim

Investment in oncology drug development remains strong, with 133 firm initiating late-stage trials

Article | 03 June 2011

Print This

Trials targeting non-small cell lung cancer, breast cancer and multiple hematological cancers are amongst the most active, while Roche and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in